Current Landscape and the Attribution Hurdle For this event to resolve, a novel compound must clear a strict set of criteria: discovery clearly credited to a general-purpose AI, a completely new mechanism of action, progression through IND-enabling and Phase 1 safety work, and finally, a human efficacy readout against a WHO critical-priority Gram-negative pathogen (such as CRAB, CRE, or third-generation-cephalosporin-resistant Enterobacterales). As of October 2026, no molecule designed by a general AI model has entered human trials. The most advanced general-AI demonstration is Google DeepMind's Antigravity agent, which nominated a bacteriocin candidate that is still in wet-lab validation Google Antigravity: Accelerating Antimicrobial Peptide ... Google Antigravity: Accelerating Antimicrobial Peptide ... Google Antigravity: Accelerating Antimicrobial Peptide .... This candidate currently lacks validated critical-priority Gram-negative coverage. Meanwhile, other leading AI antibiotic programs, such as the Phare Bio and Basilea partnership, rely on purpose-built specialist models that do not meet the general-AI attribution requirement on their own Basilea and Phare Bio enter partnership combining anti ... Phare Bio and Basilea Announce Landmark Partnership to ... Basilea and Phare Bio enter partnership combining anti ... PHARE BIO.

Biological and Clinical Bottlenecks While AI is demonstrably accelerating molecular discovery and regulatory paperwork—for example, drafting an IND summary module in four hours Early progress on accelerating drug development with ...—computational hits must still be optimized into compounds with suitable exposure, tolerability, and manufacturability A novel antibiotic class targeting the lipopolysaccharide .... A useful human-found comparator is zosurabalpin, a genuinely new class against Acinetobacter, which has required roughly a decade from hit to reach a pivotal Phase 3 trial Roche to launch phase 3 trial for new antibiotic targeting ... https://assets.roche.com/f/176343/x/c1ca231e2d/pharmaq326.pdf Roche to launch phase 3 trial for new antibiotic targeting ... Zosurabalpin and the Revival of Pathogen-Specific .... Even if a general AI agent discovers a qualifying hit in 2027 and vastly compresses preclinical optimization, the fundamental biological difficulty of penetrating the Gram-negative cell wall ensures that early generations of AI-discovered leads will still face high attrition rates.

The Fastest Path The earliest plausible readouts (2030–2032) require a highly optimistic sequence of events. A general AI must rapidly identify a valid candidate or repurpose an existing safe compound with a novel antibacterial mechanism by 2027 or 2028. From there, AI-accelerated preclinical development would need to yield an IND by 2029. This would have to be followed directly by a streamlined, limited-population trial Limited Population Pathway for Antibacterial and ... or a fast-enrolling Phase 2 study—perhaps in complicated urinary tract infections enriched for CRE—that meets a pre-specified efficacy endpoint within two years. I place a 10% probability of a qualifying result by September 1, 2030, and a 25% probability by June 1, 2032.

The Median and the Long Tail My median date of June 1, 2035, accounts for the grueling reality of clinical development in antimicrobial resistance. Enrolling patients with carbapenem-resistant infections is notoriously slow, often taking years Novel Antimicrobial Drug Development and Access:, and weak commercial incentives can limit the funding necessary to rapidly execute registration trials An evaluation of the US public–private Combating Antibiotic .... These antibiotic-specific trial challenges naturally place this milestone later than broader medical breakthroughs, even if AI accelerates other parts of drug development. The long right tail, extending into the mid-2040s, reflects compounding risks. Candidates may repeatedly fail due to toxicity, AI systems might struggle to design entirely novel mechanisms that actually work in vivo, and there are strict definitional constraints to clear. For instance, Pseudomonas aeruginosa is only in the high-priority, not critical-priority, category on the 2024 WHO list WHO Bacterial Priority Pathogens List, 2024, narrowing the target space. Furthermore, any ambiguity in attribution between specialist tools and general models could invalidate otherwise successful drugs. These combined factors could easily push a qualifying result back by decades. I therefore place a 75% probability of a qualifying result by June 1, 2039, and a 90% probability by December 31, 2045.